Bristol-Myers Squibb Co.: PharmaVitae Profile now available at ReportsandReports

0

Dallas, TX: ReportsandReports announce Bristol-Myers Squibb Co.: PharmaVitae Profile Market Research Report in its Store.

 

Browse complete Report at http://www.reportsandreports.com/market-reports/bristol-myers-squibb-co-pharmavitae-profile/

 

This analysis examines the historical and forecast performance for BMS in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

  • Benchmark Bristol-Myers Squibb's performance against key rivals in the ethical pharmaceutical sector
  • Assess how BMS is exploring the fast-growth oncology and immunology disease markets to drive long-term sales in the face of blockbuster patent expiry
  • Investigate the strength of BMS's pipeline, its product collaborations with AstraZeneca and Pfizer and the recent acquisition of Medarex.

Table Of Contents

ABOUT DATAMONITOR HEALTHCARE

About the PharmaVitae team

Chapter 1 About this profile

PharmaVitae Explorer database

Chapter structure

Executive summary

Quarterly update

Company introduction

Company sales

Company financials

Key products

Data sourcing

Sales data

Analyst consensus

Chapter 2 Executive summary

Key findings

Prescription pharmaceutical sales and growth rate performance, 2003-15

Financial performance, 2003-15

Bristol-Myers Squibb: PharmaVitae forecasts at a glance

Strategic insight

Plavix dependency pushes BMS over 2012 patent cliff

BMS has the second fastest expiry decline within Big Pharma

BMS will focus on areas of high unmet need to mitigate the decline of its CV portfolio

BMS builds Big Pharma collaborations

Pfizer collaboration for apixaban

Antidiabetic collaboration with AstraZeneca

BMS fast evolving into a fully-fledged biopharmaceutical player

Productivity transformation initiative expected to lower operating costs by $2.5 billion by 2012

Increasingly profitable business model makes BMS an attractive M&A target

SWOT analysis

Table of Contents

Table of figures

Chapter 3 Quarterly news update

Latest quarterly sales

Latest comment

Q2 2010

ASCO 2010: ipilimumab achieves breakthrough in 'long dark tunnel' of metastatic melanoma

ASCO 2010: first-line chronic myeloid leukemia becomes next battleground for Sprycel and Tasigna

EASL 2010: promising developments in the hepatitis C pipeline

Q1 2010

Slow growth in cardiovascular disease will be offset by prospects in diabetes

Latest prescription pharma product news

Q3 2010

Q2 2010

Q1 2010

Latest corporate news

Q2 2010

Q1 2010

Future product milestones

Chapter 4 Company introduction

Key findings

Background

Key corporate developments

Bristol-Myers

Squibb

Bristol-Myers Squibb

M&A history

Medarex

Kosan Biosciences

Adnexus Therapeutics

Acordis Speciality Fibres

DuPont Pharmaceuticals

Mead Johnson

ConvaTec

Medical Imaging

Consumer Medicines

Oncology Therapeutics Network

Corporate restructuring to focus on pharma

Chapter 5 Company sales

Key findings

Prescription pharmaceutical sales and growth rate analysis, 2003-15

Historical analysis

Forecast analysis

Product analysis

Product analysis, 2003-09

Product analysis, 2009-15

Therapy area analysis

Geographic analysis

Launch/core/expiry analysis

Explanation of launch/core/expiry analysis

Launch analysis, 2009-15

Core analysis, 2009-15

Expiry analysis, 2009-15

Launch/core/expiry configuration, 2009-15

Molecule type analysis

Externalization analysis

Chapter 6 Company financials

Key findings

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003-09

Operating costs and profit analysis

Operating costs and profit analysis, 2003-09

Operating cost ratio and profit margin analysis, 2003-09

Operating cost ratio and profit margin analysis, 2009-15

Operating costs and profit analysis, 2009-15

Chapter 7 Key products

Overview

Plavix

Summary

Sales forecast

Reyataz

Summary

Sales forecast

Baraclude

Summary

Sales forecast

Orencia

Summary

Sales forecast

Sprycel

Summary

Sales forecast

Onglyza

Summary

Sales forecast

Erbitux

Summary

Sales forecast

Belatacept

Summary

Sales forecast

Sustiva

Summary

Sales forecast

Ipilimumab

Summary

Sales forecast

Abilify

Summary

Sales forecast

Ixempra

Summary

Sales forecast

Chapter 8 Appendix

References

Abbreviations

Exchange rates

About Datamonitor

About Datamonitor Healthcare

Datamonitor consulting

Disclaimer

List of Tables

Table 1: Bristol-Myers Squibb - PharmaVitae forecasts at a glance

Table 2: Expiry sales across Big Pharma ($m), 2009 & 2015

Table 3: Bristol-Myers Squibb quarterly sales ($m), Q109-Q110

Table 4: Bristol-Myers Squibb future product milestones, 2010-12

Table 5: Bristol-Myers Squibb product portfolio overview ($m), 2003-09

Table 6: Bristol-Myers Squibb product portfolio overview ($m), 2009-15

Table 7: Bristol-Myers Squibb prescription pharmaceutical sales by therapy area ($m), 2009-15

Table 8: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region ($m), 2009-15

Table 9: Bristol-Myers Squibb launch portfolio overview ($m), 2009-15

Table 10: Bristol-Myers Squibb core portfolio overview ($m), 2009-15

Table 11: Bristol-Myers Squibb expiry portfolio overview ($m), 2009-15

Table 12: Bristol-Myers Squibb prescription pharmaceutical sales by molecule type ($m), 2009-15

Table 13: Bristol-Myers Squibb prescription pharmaceutical sales by source ($m), 2009-15

Table 14: Total Bristol-Myers Squibb sales by business unit ($m), 2003-09

Table 15: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2003-09

Table 16: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2003-09

Table 17: Bristol-Myers Squibb operating cost ratio analysis (% of total revenues), 2009-15

Table 18: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2009-15

Table 19: Bristol-Myers Squibb Key products overview

Table 20: Plavix: overview

Table 21: Plavix: sales forecast ($m), 2009-15

Table 22: Reyataz: overview

Table 23: Reyataz: sales forecast ($m), 2009-15

Table 24: Baraclude: overview

Table 25: Baraclude: sales forecast ($m), 2009-15

Table 26: Orencia: overview

Table 27: Orencia: sales forecast ($m), 2009-15

Table 28: Sprycel: overview

Table 29: Sprycel: sales forecast ($m), 2009-15

Table 30: Onglyza: overview

Table 31: Onglyza: sales forecast ($m), 2009-15

Table 32: saxagliptin + metformin: sales forecast ($m), 2009-15

Table 33: Erbitux: overview

Table 34: Erbitux: sales forecast ($m), 2009-15

Table 35: Belatacept: overview

Table 36: Belatacept: sales forecast ($m), 2009-15

Table 37: Sustiva: overview

Table 38: Sustiva: sales forecast ($m), 2009-15

Table 39: Ipilimumab: overview

Table 40: Ipilimumab: sales forecast ($m), 2009-15

Table 41: Abilify: overview

Table 42: Abilify: sales forecast ($m), 2009-15

Table 43: Ixempra: overview

Table 44: Ixempra: sales forecast ($m), 2009-15

Table 45: Exchange rates, 2010

List of Figures

Figure 1: The PharmaVitae Explorer

Figure 2: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15

Figure 3: Bristol-Myers Squibb's financial performance ($m), 2003-15

Figure 4: BMS's exposure to Plavix ($m), 2003-15

Figure 5: Launch portfolio outlook across Big Pharma

Figure 6: BMS's therapy area focus, 2003-15 (% total prescription pharma sales)

Figure 7: Total prescription pharma market sales growth by therapy area, 2009-15 CAGR (%)

Figure 8: Bristol-Myers Squibb SWOT analysis

Figure 9: Bristol-Myers Squibb prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15

Figure 10: Bristol-Myers Squibb Key product sales ($m), 2003-15

Figure 11: Bristol-Myers Squibb key sales growth drivers and resistors ($m), 2003-09

Figure 12: Bristol-Myers Squibb key sales growth drivers and resistors ($m), 2009-15

Figure 13: Bristol-Myers Squibb prescription pharmaceutical sales by therapy area ($m), 2003-15

Figure 14: Bristol-Myers Squibb prescription pharmaceutical sales by geographic region ($m), 2003-15

Figure 15: Bristol-Myers Squibb launch/core/expiry configuration ($m), 2009-15

Figure 16: Bristol-Myers Squibb prescription pharmaceutical sales by molecule type ($m), 2003-15

Figure 17: Bristol-Myers Squibb prescription pharmaceutical sales by source ($m), 2003-15

Figure 18: Bristol-Myers Squibb operating revenue/cost analysis ($m), 2003-15

Figure 19: Plavix sales by geography and analyst consensus ($m), 2003-15

Figure 20: Reyataz sales by geography and analyst consensus ($m), 2003-15

Figure 21: Baraclude sales by geography and analyst consensus ($m), 2003-15

Figure 22: Orencia sales by geography and analyst consensus ($m), 2003-15

Figure 23: Sprycel sales by geography and analyst consensus ($m), 2003-15

Figure 24: Onglyza sales by geography and analyst consensus ($m), 2003-15

Figure 25: saxagliptin + metformin sales by geography and analyst consensus ($m), 2003-15

Figure 26: Erbitux sales by geography and analyst consensus ($m), 2003-15

Figure 27: Belatacept sales by geography and analyst consensus ($m), 2003-15

Figure 28: Sustiva sales by geography and analyst consensus ($m), 2003-15

Figure 29: Ipilimumab sales by geography and analyst consensus ($m), 2003-15

Figure 30: Abilify sales by geography and analyst consensus ($m), 2003-15

Figure 31: Ixempra sales by geography and analyst consensus ($m), 2003-15

 

Browse all Healthcare Market Research Reports

Browse all Datamonitor Market Research Reports

Browse all Newly Published Market Research Reports

 

Related Reports:

Bristol-Myers Squibb Co.-Deals & Alliances Report

Bristol-Myers Squibb Company-Therapeutic Competitors

Bristol-Myers Squibb Company-Detailed Product Pipeline

 

About Us:

Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

 

Contact:

Ms. Sunita

7557 Rambler road,

Suite 727, Dallas, TX 75231

Tel: +1-888-989-8004

Website: http://www.reportsandreports.com/

Blog: http://reportsnreports.wordpress.com/

Blog: http://reportsandreports.blogspot.com/

Customer comments

No comments were found for Bristol-Myers Squibb Co.: PharmaVitae Profile now available at ReportsandReports. Be the first to comment!